

OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest

Nantes - November 15, 2016 - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, today announced that it has received both the First and "Listed Company" prizes as part of the 2016 Deloitte In Extenso Technology Fast 50 Ouest, an initiative that rewards fast growing companies.

Companies are ranked according to the growth of their revenues during the four previous years. OSE Immunotherapeutics was awarded the "Listed Company" prize for the Company's significant growth rate of +1900% between 2012 and 2015.

Maryvonne Hiance, Vice-Chairman and Director of the Strategy of OSE Immunotherapeutics :

"We are very proud to have topped Deloitte's rankings, which signifies that we are one of France's fastest growing companies over the past four years. This prize recognizes our corporate strategy and rewards the expertise of our team and their commitment to the company's development."

Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics:

"Since the end of 2015, with the continued development of our first-in-class product candidates, ranging from R&D to the clinical registration phase, a first global agreement with Janssen Biotech Inc. and a reinforced cash position, OSE Immunotherapeutics is well-positioned to drive further future growth. »

Laurent Halfon, Deloitte Partner and country manager of the Technology Fast 50 programme in France:

"The Technology Fast 50 ranking promotes companies like OSE Immunotherapeutics which reflect the incredible drive for innovation and added value creation of French entrepreneurs. Already in its 16th edition, the Technology Fast 50 France ranking has become a true reference for French and international investors. We are proud to see OSE Immunotherapeutics among the winners for 2016."

The ranking is open to any company that meets the following, cumulative criteria:

- The company is an independent, French company;
- The company holds patents and/or allocates at least 5% of its annual revenues to Research & Development and is active in one of the six following industries: 1) Biotechnology and Life Sciences 2) Energy and Green Technologies 3) Hardware and Electronics 4) Internet, Media and Telecommunications 5) Software and IT services, 6) Aerospace and Defense.
- The company was created before January 1st, 2012, and has successfully concluded at least four financial years of twelve months each;
- The company reported revenues of at least 50 000 euros in 2012.



ABOUT OSE IMMUNOTHERAPEUTICS

Our ambition is to become a world leader in activation and regulation immunotherapies

OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.

The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:

- **Tedopi®**, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - **currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US** - Orphan Status in the US - **registration expected in 2019** - a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 - the product is also **considered in other cancer indications.**
- **FR104**, CD28-antagonist in immunotherapy - **Phase 1 trial completed** – for the treatment of autoimmune diseases and for use with transplantation - **licensed to Janssen Biotech Inc.** to pursue clinical development
- **Effi-7**, interleukin receptor 7 antagonist - **in preclinical development** for inflammatory bowel diseases and other autoimmune diseases
- **Effi-DEM**, new generation checkpoint inhibitor targeting the **SIRP-α receptor** - **in preclinical development** for immuno-oncology
- **R&D:** candidates targeting new receptors in immuno-oncology

The portfolio's blockbuster potential gives OSE Immunotherapeutics the ability to enter global agreements at different stages of development with major pharmaceutical players.

Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at \$67 billion in 2018 **.

There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales towards \$10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.

*Citi Research Equity
**BCC Research

More information: <http://ose-immuno.com>

Click and follow us on Twitter and LinkedIn



About Deloitte Technology Fast 50 France

Now in its sixteenth year, the Technology Fast 50 France is part of an international programme run by Deloitte. Qualifying entrants of the Fast 50 France will be put forward to the Deloitte Technology Fast 500 EMEA (Europe, Middle East and Africa) programme, along with entrants from other national programmes run by Deloitte in the EMEA region.

The Deloitte Technology Fast 50 awards recognise and profile French technology companies, public or private, including some of the most dynamic players in all areas of technology, from Internet specialists to biotech, digital media technology to life sciences, computers to semiconductors and software to telecommunications.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. In France, Deloitte SAS is the member firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates.

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's approximately 244,000 professionals are committed to becoming the standard of excellence.

In France, Deloitte calls on diversified expertise to meet the challenges of its clients of all sizes from all industries - major multinationals, local micro-companies and medium-sized enterprises. With the expertise of its 10 300 professionals and partners, Deloitte is a leading player in audit, risk advisory, consulting, financial advisory, tax & legal and accounting, based on a multidisciplinary offering and a set of action principles attuned to the requirements of our environment.

Contacts

Deloitte

Sarah Lheritier
Media Relations, Deloitte
+ 33 (0) 1 55 61 48 65
slheritier@deloitte.fr

OSE Immunotherapeutics

Dominique Costantini, CEO
dominique.costantini@ose-immuno.com
+33 613 207 749

Maryvonne Hiance, Vice-Chairman and Director of Strategy
maryvonne.hiance@ose-immuno.com
+33 680 060 183

Alexis Peyroles, COO, Finance, BD & Operations
alexis.peyroles@ose-immuno.com
+33 611 511 977

Bernard Vanhove, COO, R&D, International scientific collaborations
Bernard.vanhove@ose-immuno.com
+33 675 414 008

Contacts media

Alize RP
Florence Portejoie & Caroline Carmagnol
oseimmuno@alizerp.com
+33 647 389 004

LifeSci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Acorelis

Gilles Petitot
+33 620 276 594
gilles.petitot@acorelis.com

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.16-052, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.